This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Check our privacy policy here
Our Blog
USC and SunRock launch a joint unit to accelerate therapies for cancer and inflammatory diseases
17/04/2026The initiative, coordinated by Professor Mabel Loza from CiMUS, will be funded with €2.73 million over nearly three years and is…
Read More
SunRock Biopharma, S.L will be attending the BIO-Europe Spring 2026 in Lisbon from 23-25 March
10/03/2026We are a biotech company with a pipeline of therapeutic antibodies for the treatment of cancer and immune-mediated inflammatory diseases, including…
Read More
SunRock Biopharma, S.L will be attending the BIO-Europe 2025 in Vienna from 3-5 November
22/10/2025We are a biotech company with a pipeline of therapeutic antibodies for the treatment of cancer and immune-mediated inflammatory diseases, including…
Read More
SunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB5
20/10/2025Santiago de Compostela (Spain) / Wuhan (China), September, 2025 — SunRock Biopharma, a biotechnology company focused on developing next-generation therapeutic antibodies,…
Read More
UEG Week 2025: SunRock along with Dr. Manuel Barreiro presented promising results with its anti-CCR9 antibodies in IBD
07/10/2025SunRock participated in UEG Week 2025, held in Berlin from October 4 to 7, where our collaborator Dr. Manuel Barreiro, Head…
Read More
Galician company SunRock launches itself onto the world stage from Biopolo with an innovative anti-tumor drug
06/10/2025Link: https://www.elcorreogallego.es/economia/2025/10/06/gallega-sunrock-proyecta-mundo-biopolo-122301872.amp.html
Read More
SunRock Biopharma will be presenting results on its anti-CCR9 antibody for IBD in a poster at UEG Week, Berlin 2025
01/10/2025Our Manager, Juan Buela and Elia Alvarez, our Senior Scientist, will be attending UEG Week 2025 in Berlin (October 4–7), and…
Read More
DEBIOPHARM LICENSES SUNROCK BIOPHARMA’S ANTI-HER3/HER2 ANTIBODY TO EXPLORE THE FULL POTENTIAL OF BISPECIFIC ADC DEBIO 2512
30/09/2025Lausanne, Switzerland and Santiago De Compostela, Spain – September 30th, 2025 – Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company today announced…
Read More
SunRock Biopharma and Escugen Forge Alliance to Develop First-in-Class CCR9-Targeted ADC
17/06/2025SunRock Biopharma and Escugen Forge Alliance to Develop First-in-Class CCR9-Targeted ADC Santiago de Compostela, Spain, and Shanghai, China . June 16,…
Read More
SunRock is pleased to share a new publication in Molecular Oncology highlighting the potential of SRB2 in pancreatic ductal adenocarcinoma
03/06/2025SRB2 is a humanized monoclonal #antibody developed by SunRock Biopharma, S.L targeting #CCR9. 🎯 This study demonstrates the efficacy of SRB2…
Read More
